CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
225Ac-J591drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03276572
NCT03276572Phase 1Completed
CompareCT.gov

Phase I Dose-Escalation Trial of 225Ac-J591 in Patients With Metastatic Castration-Resistant Prostate Cancer

Weill Medical College of Cornell University·interventional·Posted Sep 8, 2017·Updated Jun 13, 2024

In Brief

A Phase 1 clinical trial evaluating 225Ac-J591 for Prostate Cancer. Completed, enrolled 32 participants across 2 sites.

Detailed Summary

This is an open-label, single-center Phase I dose escalation study designed to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac-J591 in a single dose regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsProstate Cancer Foundation, United States Department of Defense, National Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 8, 2017
Enrollment StartOct 10, 2017
Primary CompletionJan 7, 2021
Study CompletionSep 1, 2023
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.8 years ago

Interventions

225Ac-J591drug

225Ac-J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1